Skip to main content

Clovis Oncology, Inc.

CLVSDelisted Dec 29, 2022
Industry
Pharmaceutical Preparations
SEC CIK
0001466301

Clovis Oncology, Inc. was delisted on Dec 29, 2022; its insiders filed their last Form 4 on Nov 3, 2022; 103 institutions reported holding it in 13F filings for Q3 2022, worth $42.6M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Clovis Oncology, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Clovis Oncology, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Clovis Oncology, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Ivers-Read Gillian CSee Remarks293,612Nov 3, 20220
Muehl Daniel WSee Remarks104,830Nov 3, 20220
Rolfe LindseySee Remarks113,691Nov 3, 20220
Gross Paul EdwardSee Remarks98,330Nov 3, 20220
Harding Thomas C.See Remarks3,801IndirectNov 3, 20220
Mahaffy Patrick JSee Remarks–Mar 3, 20220
Simantov RonitDirector–Jul 13, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 3, 2022 (view filing)Jun 21 dayHarding Thomas C.See RemarksSSale−1.50K$0.64−$962.56−9.3%14.7K after
Jun 3, 2022 (view filing)Jun 21 dayHarding Thomas C.See RemarksSSale−218$0.64−$139.52−6.3%3.23K after
Jul 6, 2022 (view filing)Jul 51 dayHarding Thomas C.See RemarksSSale−7$2.71−$18.97−0.2%3.23K after
Aug 3, 2022 (view filing)Aug 21 dayHarding Thomas C.See RemarksSSale−1.73K$1.46−$2.53K−9.6%16.4K after2 lots
Aug 3, 2022 (view filing)Aug 21 dayHarding Thomas C.See RemarksSSale−77$1.46−$112.42−2.3%3.34K after
Aug 3, 2022 (view filing)Aug 21 dayGross Paul EdwardSee RemarksSSale−4.81K$1.46−$7.02K−5.1%90.1K after2 lots
Aug 3, 2022 (view filing)Aug 21 dayIvers-Read Gillian CSee RemarksSSale−3.80K$1.46−$5.55K−1.3%286.1K after2 lots
Aug 3, 2022 (view filing)Aug 21 dayRolfe LindseySee RemarksSSale−4.33K$1.46−$6.32K−3.9%107.1K after2 lots
Aug 3, 2022 (view filing)Aug 21 dayMuehl Daniel WSee RemarksSSale−4.65K$1.46−$6.79K−4.6%96.3K after2 lots
Sep 6, 2022 (view filing)Sep 24 daysMuehl Daniel WSee RemarksSSale−2.23K$1.20−$2.68K−2.2%99.2K after
Sep 6, 2022 (view filing)Sep 24 daysIvers-Read Gillian CSee RemarksSSale−2.23K$1.20−$2.68K−0.8%288.9K after
Sep 6, 2022 (view filing)Sep 24 daysHarding Thomas C.See RemarksSSale−1.44K$1.20−$1.73K−7.5%17.8K after
Sep 6, 2022 (view filing)Sep 24 daysHarding Thomas C.See RemarksSSale−172$1.20−$206.4−4.5%3.67K after
Sep 6, 2022 (view filing)Sep 24 daysGross Paul EdwardSee RemarksSSale−2.31K$1.20−$2.77K−2.4%92.8K after
Sep 6, 2022 (view filing)Sep 24 daysRolfe LindseySee RemarksSSale−2.54K$1.20−$3.05K−2.3%109.6K after
Oct 4, 2022 (view filing)Oct 31 dayHarding Thomas C.See RemarksSSale−6$1.29−$7.74−0.2%3.68K after
Nov 3, 2022 (view filing)Nov 21 dayRolfe LindseySee RemarksSSale−4.26K$0.98−$4.18K−3.6%113.7K after2 lots
Nov 3, 2022 (view filing)Nov 21 dayMuehl Daniel WSee RemarksSSale−4.58K$0.98−$4.49K−4.2%104.8K after2 lots
Nov 3, 2022 (view filing)Nov 21 dayHarding Thomas C.See RemarksSSale−1.70K$0.98−$1.67K−8.0%19.5K after2 lots
Nov 3, 2022 (view filing)Nov 21 dayHarding Thomas C.See RemarksSSale−63$0.98−$61.74−1.6%3.80K after
Nov 3, 2022 (view filing)Nov 21 dayIvers-Read Gillian CSee RemarksSSale−3.68K$0.98−$3.61K−1.2%293.6K after2 lots
Nov 3, 2022 (view filing)Nov 21 dayGross Paul EdwardSee RemarksSSale−4.73K$0.98−$4.64K−4.6%98.3K after2 lots